文献速递慢阻肺

重新审视血嗜酸性粒细胞评估慢阻肺吸入激素反应:FLAME试验事后分析

Rethinking Blood Eosinophils for Assessing Inhaled Corticosteroids Response in COPD: A Post Hoc Analysis From the FLAME Trial.
PubMed 文献 · Chest · 2024-07-09

该研究为FLAME试验事后分析,比较使用吸入激素(ICS)期间、停用ICS期间及ICS治疗前后血嗜酸性粒细胞计数(BEC)变化对COPD患者ICS治疗反应的预测价值。结果显示停用ICS时BEC或ICS治疗期间BEC变化比使用ICS时BEC更能预测ICS获益,且ICS相关肺炎风险似乎仅限于无获益患者。

要点

  • 停用ICS时BEC或ICS治疗期间BEC变化比使用ICS时BEC更能预测ICS治疗反应。
  • 约9%参与者ICS治疗期间BEC显著变化(≥200 cells/μL),此时使用ICS时BEC不预测反应。
  • ICS相关肺炎超额风险似乎仅限于未从ICS治疗中获益的患者。

核心结论

  • 优先使用停用ICS时BEC或ICS治疗期间BEC变化来指导COPD患者ICS治疗决策,使用ICS时BEC预测性较差。

研究设计与样本

  • FLAME试验为52周双盲随机对照试验,比较LABA/LAMA与LABA/ICS, run-in期4周禁止使用皮质激素。
  • 本分析为事后分析,选取既往使用ICS的患者,以run-in前后BEC分别代表使用ICS时和停用ICS时BEC。

主要发现

  • 对多数FLAME参与者,LABA/LAMA在减少急性加重方面优于或至少非劣于LABA/ICS。
  • 停用ICS时BEC更高、使用ICS时BEC更高及ICS治疗期间BEC显著抑制,均与LABA/ICS在急性加重率、首次急性加重时间和首次肺炎时间方面更优反应相关。
  • 在占9%参与者的亚组中,ICS治疗期间BEC变化显著(≥200 cells/μL),使用ICS时BEC不预测ICS治疗反应,而停用ICS时BEC和BEC变化更具预测性。
  • BEC不能预测治疗对肺功能和健康状况的影响。

关键数值与推荐

  • ICS治疗期间BEC变化显著定义为≥200 cells/μL,见于9%的参与者。

临床怎么用

  • 临床决策时应优先参考停用ICS时的BEC或ICS治疗期间的BEC变化,而非使用ICS时的BEC。
  • 对ICS治疗期间BEC显著变化(≥200 cells/μL)的患者,应结合停用ICS时BEC和BEC变化评估ICS获益。

局限性

  • 本研究为FLAME试验的事后探索性分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The varied treatment response to inhaled corticosteroids (ICS) in patients with COPD and the associated increased risk of pneumonia necessitate a personalized ICS therapeutic approach. This is informed by blood eosinophil count (BEC), which predicts ICS treatment response. However, BEC appears to change in response to ICS treatment. RESEARCH QUESTION: Does (1) BEC measured on ICS treatment (2) BEC measured off ICS treatment, or (3) the change in BEC during ICS treatment best predict treatment response to ICS in COPD? STUDY DESIGN AND METHODS: The Fluticasone Salmeterol on COPD Exacerbations Trial (FLAME), a 52-week, double-blind randomized controlled trial compared long-acting beta-2 agonists (LABAs)/long-acting muscarinic antagonists (LAMAs) with LABA/ICS. Corticosteroids were prohibited during a 4-week run-in period. We chose patients previously on ICS, thereby allowing BEC before and after the run-in period to represent BEC on and off ICS, respectively. In this post hoc analysis, we revisited outcome data, exploring how the three BEC biomarkers interacted with treatment response to the ICS-containing regimen. RESULTS: Our study showed that LABA/LAMA combination was superior, or at least noninferior, to LABA/ICS in curbing exacerbations for most FLAME participants. However, higher BEC off ICS, higher BEC on ICS, and significant BEC suppression during ICS treatment corresponded to superior response to LABA/ICS in terms of exacerbation rate, time to first exacerbation, and time to first pneumonia. In a subgroup, including 9% of participants, BEC changed significantly during ICS treatment (≥ 200 cells/μL), and higher BEC on ICS did not predict ICS treatment response. For these patients, BEC off ICS and BEC change proved more predictive. Excess pneumonia risk associated with ICS appeared to be confined to patients who do not benefit from this treatment. BEC was not predictive of treatment effects on lung function and health status. INTERPRETATION: This exploratory analysis advocates preferentially using BEC off ICS or BEC change during ICS treatment for guiding ICS treatment decisions. BEC measured on ICS is less predictive of treatment response. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov; No.: NCT01782326; URL: www. CLINICALTRIALS: gov.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Mathioudakis, Bate, Sivapalan, et al. Rethinking Blood Eosinophils for Assessing Inhaled Corticosteroids Response in COPD: A Post Hoc Analysis From the FLAME Trial. Chest. 2024. PMID: 38992490. doi:10.1016/j.chest.2024.06.3790

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。